The price of Kerendia 10 mg can vary depending on factors such as insurance coverage, pharmacy, and geographic location. The estimated retail price for a 30-day supply of Kerendia 10 mg oral tablets is approximately $525 [1].
What might influence the cost of Kerendia?
Several elements can affect the final cost of Kerendia. Insurance plans often have different tiers for medications, which can impact the co-pay amount. Patient assistance programs or discount cards may also be available, potentially lowering out-of-pocket expenses [1]. Prescription drug costs are also subject to change over time and can differ between various pharmacies, including large chain pharmacies and independent drugstores.
Where can I find savings or discounts for Kerendia?
Savings options for Kerendia may include manufacturer coupons or discount programs. These can sometimes reduce the co-pay for eligible commercially insured patients [1]. Information on such programs is typically available through the drug manufacturer's website or by asking a pharmacist.
When might Kerendia's patent expire?
Understanding patent exclusivity is crucial for anticipating future pricing and the potential for generic alternatives. According to DrugPatentWatch.com, the earliest patent expiration for Kerendia is expected in 2036 [2]. However, patent landscapes can be complex and involve multiple patents covering different aspects of the drug, such as composition, method of use, and manufacturing [2]. Litigation or new patent filings can alter these timelines.
Are there alternatives to Kerendia?
While Kerendia (finerenone) is a specific medication indicated for chronic kidney disease associated with type 2 diabetes, other treatment approaches exist for managing this condition. These might include other classes of medications that target different pathways involved in kidney disease progression, lifestyle modifications, and management of underlying conditions like diabetes and hypertension [3]. However, direct therapeutic alternatives depend on individual patient needs and physician recommendations.
How does Kerendia work to treat kidney disease?
Kerendia's active ingredient, finerenone, is a non-steroidal mineralocorticoid receptor antagonist. It works by blocking the detrimental effects of excessive mineralocorticoid receptor (MR) activity in the kidneys and heart. This action helps to reduce inflammation and fibrosis, thereby slowing the progression of chronic kidney disease in patients with type 2 diabetes [4].
What clinical data supports Kerendia's use?
Clinical trials have evaluated Kerendia's efficacy and safety. The FIDELIO-DKD and FIGARO-DKD trials, for example, demonstrated that finerenone significantly reduced the risk of kidney disease progression and cardiovascular events in patients with type 2 diabetes and chronic kidney disease [4]. These studies are foundational to its regulatory approval.
What are the reported side effects of Kerendia?
Common side effects associated with Kerendia include hyperkalemia (high potassium levels), hypotension (low blood pressure), and diarrhea [4]. Patients should discuss potential side effects and their management with their healthcare provider. Regular monitoring of potassium levels and kidney function is generally recommended during treatment [4].
Who manufactures Kerendia?
Kerendia is manufactured by Bayer [4].
---
Sources:
1. GoodRx
2. DrugPatentWatch.com
3. Information on general treatment approaches for chronic kidney disease associated with type 2 diabetes is based on established medical guidelines. Specific alternative medications would require consultation with a healthcare professional.
4. Bayer Pharmaceuticals